Compositions of matter and pharmaceutical compositions
Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.
1 . A method of treating depression in a subject in need thereof, the method comprising mucosally administering to the subject:
a therapeutically effective amount of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof,
wherein the mucosal administration provides absorption of the 5-MeO-DMT into the blood of the subject after administration.
2 . The method of claim 1 , wherein the mucosal administration is sublingual, buccal, nasal, inhalation, or oral.
3 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a strip, a solution, a suspension, a gel, a liquid, an emulsion, liposomes, microparticles, a film, a powder, or a patch.
4 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a spray.
5 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a film.
6 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a strip.
7 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a solution.
8 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a suspension.
9 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a gel.
10 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a liquid.
11 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a sublingual strip.
12 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of microparticles.
13 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a pharmaceutical composition comprising 5-MeO-DMT and a pharmaceutically acceptable carrier.
14 . The method of claim 1 , wherein the mucosal administration comprises administration to the nasal mucosa, lung mucosa, gastric mucosa, esophageal mucosa, or intestinal mucosa.
15 . The method of claim 14 , wherein about 5 mg to about 25 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.
16 . The method of claim 15 , wherein about 6 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.
17 . The method of claim 15 , wherein about 8 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.
18 . The method of claim 15 , wherein about 12 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.
19 . The method of claim 15 , wherein about 18 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.
20 . The method of claim 16 , wherein the method further comprises subsequently administering about 12 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to the subject.
21 . The method of claim 18 , wherein the method further comprises subsequently administering about 18 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to the subject.
22 . The method of claim 20 , wherein the method further comprises subsequently administering about 18 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to the subject.